Loomis Sayles
Loomis Sayles Growth Fund
Mega-cap Growth
Dec 2024 → Sep 2025
Our archive holds 4 letters from this strategy, behind 10 investment theses and positions in 12 companies. Every quote below is copied verbatim from the letter it came from.
4 letters in 2 years · follow all of Loomis Sayles for every strategy.
What it bought and sold
During the quarter, we added to our existing positions in Novo Nordisk and Vertex as near-term price weaknesses created attractive reward-to-risk opportunities.
We trimmed our position in Alibaba to finance the purchases.
During the quarter, we added to our existing positions in Novo Nordisk and Vertex as near-term price weaknesses created attractive reward-to-risk opportunities.
Also held
Its investment theses
- NetflixSep 2025Netflix is poised for significant growth as it capitalizes on the shift to streaming, increasing its share of global consumer spending and improving operating margins, making it a compelling investment opportunity.
- TeslaSep 2025Tesla is well-positioned for long-term growth due to increasing electric vehicle adoption, advances in autonomous driving technology, and strong profit potential from high-margin software offerings.
- NetflixJun 2025Netflix is positioned to capitalize on the shift to streaming, likely increasing its share of global consumer entertainment spending and generating sustainable growth in free cash flow, resulting in a significant reward-to-risk investment opportunity.
- Thermo Fisher ScientificJun 2025Thermo Fisher Scientific (TMO) is well-positioned for long-term growth in the life sciences tools industry, with a strong focus on biopharma, anticipated high-single-digit revenue growth, and undervalued share price offering a compelling investment opportunity despite current market pessimism.
- Vertex PharmaceuticalsJun 2025Vertex is a compelling long-term investment opportunity due to its strong competitive advantages in cystic fibrosis therapies, ongoing innovation, and significant growth potential in revenues and cash flow.
- NvidiaMar 2025Nvidia is poised for significant long-term growth driven by its dominance in data center revenues, particularly in AI computing, strong gaming prospects, and a high-quality financial model, leading to a compelling investment opportunity at a discounted share price.
- Vertex PharmaceuticalsMar 2025Vertex is well-positioned for long-term growth due to its dominance in cystic fibrosis therapies, strong partnerships, and a robust pipeline of innovative treatments, presenting a compelling investment opportunity at a significant discount to its intrinsic value.
- VisaMar 2025Visa is well-positioned for long-term growth in the expanding digital payments market, with significant opportunities beyond its current consumer business that make its shares undervalued.
- NetflixDec 2024Netflix is poised for long-term growth with an improving financial model, increasing operating margins, and a significant opportunity in the global streaming market, leading to strong free cash flow and a compelling investment opportunity.
- Vertex PharmaceuticalsDec 2024Vertex is trading at a significant discount to its intrinsic value, driven by its strong CF franchise, innovative therapies, and potential for low-double-digit revenue growth.